PFE Today - Jul 14: Drug Pricing Deals Impacting Pfizer
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
PFE Today - Jul 14: Drug Pricing Deals Impacting Pfizer
-
ナレーター：
-
著者：
Let’s get into it. Today was a bit rough for Pfizer. The stock got hit as news rolled in about drug pricing deals from Donald Trump that are shaking things up for big pharma. Investors were clearly feeling the weight of that news. Plus, there was a lot of chatter about some disappointing results from a lung cancer trial. That overshadowed Pfizer’s win with Ibrance, which is supposed to be a big deal. So yeah, it seems like people were hitting the sell button pretty fast.
Now, why all the fuss? Well, it looks like these drug pricing deals could mean tighter profit margins for companies like Pfizer. The market's not really loving that, especially when you throw in a couple of price target cuts from big firms. BMO just slashed their target to $30 from $34, and Guggenheim did something similar, dropping it to $35. That’s not great for investor confidence. And when you mix that with the disappointment from the lung cancer trial, it’s no wonder folks are feeling skittish.
One thing worth mentioning is that Pfizer did get FDA approval for something recently, but the market’s reaction was pretty muted. It’s like, “Yeah, cool, but what have you done for me lately?” That kind of vibe can really affect how stocks move, and today was a clear example of that.
So, to wrap it all up: Pfizer’s facing some headwinds with drug pricing changes and trial results that didn’t quite hit the mark. It’s a tough spot, but that’s just how investing goes sometimes. Remember, this is just for fun and info, not financial advice. Catch you later!
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません